Arrhythmias & electrophysiology

Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: Insights From CABANA

JACC Heart FailPublished Secondary analysis of the CABANA randomised trial

Authors' conclusion

In patients undergoing AF ablation, the presence of underlying HFpEF (either by HFpEF probability or defined by echocardiography) was associated with a larger benefit with AF ablation on clinical outcome, AF recurrence, and functional status.

Study context

Population
Patients with atrial fibrillation (AF) and CV risk factors for stroke; high likelihood of heart failure with preserved ejection fraction (HFpEF) = modified H2FPEF score ≥655% high H2FPEF score
Participants
1,763 patients
Comparison
AF ablation vs drug therapy, by likelihood of HFpEF
Primary endpoint
CV hospitalization or death
Methodological detailssubgroup analysis
  • Subgroup analysis

Primary result

As reported in the abstract

CV hospitalization or death, AF ablation vs drug therapy, by HFpEF likelihood (modified H2FPEF score ≥6)

High likelihood of HFpEF: HR (95% CI); P

0.82

0.69–0.98P = 0.025

Without high likelihood of HFpEF: HR (95% CI); P

1.00

0.82–1.22P = 0.987

Further findings

AF recurrence, by HFpEF likelihood

Greatest ablation effect on AF recurrence with high likelihood of HFpEF
P for interaction = 0.035

Sensitivity analysis: echocardiographic HFpEF (n = 225)

Similar treatment interaction

Original publication

Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: Insights From CABANA. JACC Heart Fail. Published 16 April 2025. doi:10.1016/j.jchf.2025.01.029

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.